Results 221 to 230 of about 28,422 (269)

Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients.

British Journal of Dermatology, 2023
BACKGROUND The interest of omalizumab in bullous pemphigoid (BP) in the event of resistance or contraindication to conventional therapies is currently based on limited evidence.
Réda Chebani, F. Lombart, G. Chaby, A. Dadban, S. Debarbieux, Manuelle Viguier, S. Ingen-Housz-Oro, A. Pham‐Ledard, C. Bédane, C. Picard‐Dahan, Clémence Berthin, O. Dereure, M. Konstantinou, Marion Castel, F. Jouen, Pascal Joly, V. Seta, S. Duvert-Lehembre, C. Le Roux, G. Quéreux, B. Sassolas, E. Brenaut, C. Sin, M. Richard, F. Bérard, D. Giusti, Thibaut Belmondo, T. Gille, F. Caux, C. Prost-Squarcioni, Sabine Mignot-Grootenboer, M. Alexandre   +31 more
semanticscholar   +1 more source

Association Between Serum Total IgE Levels and Clinical Response to Omalizumab for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis.

Journal of Allergy and Clinical Immunology: In Practice, 2023
BACKGROUND Omalizumab is the only biological agent approved for patients with chronic spontaneous urticaria (CSU), but no biomarker is well-established for predicting clinical response to omalizumab.
Kai-wen Chuang, Che-Yuan Hsu, Shiu‐Wen Huang, Hua-Ching Chang   +3 more
semanticscholar   +1 more source

Combination of omalizumab with allergen immunotherapy versus immunotherapy alone for allergic diseases: A meta‐analysis of randomized controlled trials

International Forum of Allergy and Rhinology, 2023
Allergen immunotherapy (AIT)‐associated adverse events (AEs) limit its usage in the management of allergic diseases. The monoclonal anti‐IgE antibody (omalizumab) and AIT have complementary actions. However, no consensus has been reached on whether their
Ying-Ying Zhang, M. Zhang, Jia-qi Zhang, Qiu-Qi Li, Meiping Lu, Lei Cheng   +5 more
semanticscholar   +1 more source

Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort

Journal of Allergy and Clinical Immunology, 2020
BACKGROUND The EXPECT pregnancy registry was a prospective observational study established in 2006 to evaluate perinatal outcomes in pregnant women exposed to omalizumab and their infants.
Lucie Blais, Angela E Scheuerle, Michael D Cabana   +2 more
exaly   +2 more sources

Omalizumab for Asthma

New England Journal of Medicine, 2006
A 16-year-old boy with a history of severe persistent asthma despite treatment with inhaled corticosteroids presents for evaluation. Treatment with omalizumab, a monoclonal anti-IgE antibody, is recommended. This agent has been found to reduce the frequency of exacerbations of asthma in clinical trials.
Robert C, Strunk, Gordon R, Bloomberg
openaire   +2 more sources

IgE directly affects eosinophil migration in CRSwNP through CCR3 and predicts the efficacy of omalizumab.

Journal of Allergy and Clinical Immunology, 2023
BACKGROUND Whether IgE affects eosinophil migration in chronic rhinosinusitis with nasal polyps (CRSwNP) remains largely unclear. Moreover, our understanding of local IgE, eosinophils and omalizumab efficacy in CRSwNP remains limited.
Jiaqi Yu, Bing Yan, S. Shen, Yang Wang, Ying Li, F. Cao, Wei Xiong, Yingshi Piao, Chenrui Hu, Ying Sun, Luo Zhang, Chengshuo Wang   +11 more
semanticscholar   +1 more source

Omalizumab ameliorates extra-respiratory symptoms in patients with aspirin-exacerbated respiratory disease.

Journal of Allergy and Clinical Immunology, 2023
BACKGROUND Omalizumab, an anti-immunoglobulin E antibody, has clinical efficacy against respiratory symptoms of aspirin-exacerbated respiratory disease (AERD). However, some patients with AERD also present with extra-respiratory (chest, gastrointestinal,
H. Hayashi, Y. Fukutomi, C. Mitsui, K. Kajiwara, K. Watai, Y. Tomita, Y. Kamide, T. Tsuburai, K. Sekiya, Makoto Ishii, Y. Hasegawa, M. Taniguchi   +11 more
semanticscholar   +1 more source

Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence

Clinical Reviews in Allergy and Immunology, 2020
Chronic spontaneous urticaria (CSU) is defined as the spontaneous development of itchy hives and/or angioedema due to known or unknown causes that last for at least 6 weeks.
Martin Metz, Zahava Vadasz, Emek Kocaturk   +2 more
exaly   +2 more sources

Omalizumab for the Treatment of Multiple Food Allergies

New England Journal of Medicine
BACKGROUND Food allergies are common and are associated with substantial morbidity; the only approved treatment is oral immunotherapy for peanut allergy.
Robert A. Wood, A. Togias, S. Sicherer, Wayne G. Shreffler, Edwin H. Kim, Stacie M. Jones, Donald Y.M. Leung, Brian P. Vickery, J. Bird, J. Spergel, Ahmar Iqbal, Julie Olsson, Monica Ligueros-saylan, Alkaz Uddin, A. Calatroni, Charmaine Huckabee, Nicole Rogers, Nancy Yovetich, J. Dantzer, K. Mudd, Julie Wang, M. Groetch, David Pyle, C. Keet, M. Kulis, S. Sindher, Andrew J. Long, A. Scurlock, B. Lanser, Tricia Lee, Christopher P. Parrish, T. Brown-whitehorn, A. R. Spergel, Maria Veri, S. Hamrah, E. Brittain, J. Poyser, Lisa M. Wheatley, R. Chinthrajah   +38 more
semanticscholar   +1 more source

Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial.

The Lancet Respiratory Medicine
BACKGROUND Chronic rhinosinusitis with nasal polyps (CRSwNP) is predominantly driven by type 2 inflammation. The biologics dupilumab and omalizumab, which target drivers and mediators of type 2 inflammation (interleukin [IL]-4/IL-13 signaling and ...
Eugenio De Corso, G. Canonica, E. Heffler, Michal Springer, Tomasz Grzegorzek, Miguel Viana, Z. Horváth, J. Mullol, P. Gevaert, J. Michel, A.T. Peters, M. Wagenmann, S. Zaghloul, Mei Zhang, Mark Corbett, S. Nash, J. Angello, A. Radwan, Y. Deniz, Antonio Martín, P. Hellings   +20 more
semanticscholar   +1 more source